Vanguard Total World Stock ETF: 2 out of 3 targets reached, strength fading
VT is at week 6 of an open buy with 2 of 3 statistical windows already reached. Signal strength has dropped to 29 out of 100. Risk is zeroed out with the breakeven stop, but the picture calls for management, not reinforcement.
Strategy Inc: fresh short signal at week one, high-risk setup
Strategy Inc posts a fresh sell signal at week one with a strength of 36 out of 100. Our model flags trading as not recommended: opening at elevated risk per our parameters, though analysis remains active.
Microsoft: buy signal in transition, first management window in 1 week
Microsoft is in week 5 of an active buy. Signal strength stands at 59 out of 100, setup quality indicator at 52 out of 100 in ordinary phase. The first statistical management window is 1 week away.
Marvell Technology: roadmap complete, trade running with trailing stop
Marvell Technology is at week 11 of its buy signal. All 3 statistical time windows have been passed and model coverage is complete. The structural stop has trailed the rally to +87% from entry, now protecting accumulated gains.
Moderna: strong signal but a weak confirmation week
Moderna is in week 2 of a buy signal with strength at 70 out of 100. The confirmation week closed bearish: the active stop is dynamic and tighter than the structural level. The Health Care sector supports with a +2.13% weekly gain.
Merck & Co. restarts: buy signal in its opening week
Merck & Co., Inc. receives a buy signal in its opening week. The technical picture is bullish with a Setup Quality Index of 63 out of 100, but the price is hugging recent highs.